The Combination of Genistein and Imatinib has an Increased Effect on Cell Proliferation Inhibition in Philadelphia Positive Leukemia Cell Lines

E. Azizi, A. Biglari, Ali Kian Saei, S. Amanpour, S. Muhammadnejad, Mahnaz Haddadi, M. Saffari, R. Shirkoohi
{"title":"The Combination of Genistein and Imatinib has an Increased Effect on Cell Proliferation Inhibition in Philadelphia Positive Leukemia Cell Lines","authors":"E. Azizi, A. Biglari, Ali Kian Saei, S. Amanpour, S. Muhammadnejad, Mahnaz Haddadi, M. Saffari, R. Shirkoohi","doi":"10.18502/bccr.v13i1.8827","DOIUrl":null,"url":null,"abstract":"Background: This study investigated the possible role of Genistein as a combination with Imatinib in controlling leukemia cell line proliferation. \nMethods: Three cell lines, K562, Kcl22, and CCRF, were cultured and analyzed for MTT, LDH, apoptosis, and cycle cell gene expression in the presence of different dosages of Imatinib and Genistein in combination or separately. \nResults: Data has shown a decrease in proliferation and an increase in apoptosis activity during combination treatment. LDH assay has shown no additional toxicity due to Genistein consumption in combination therapy. Analysis of the expression of responsible genes for cell cycle demonstrated both G1 (p53, p21 upregulation) and G2 (cdc25c downregulation) inhibitory effect in combination treatment. \nConclusion: Altogether, this study suggests thatthe combination treatment of Imatinib and Genistein for leukemia cells resistant to Imatinib can increase treatment efficiency.","PeriodicalId":8706,"journal":{"name":"Basic & Clinical Cancer Research","volume":"134 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Basic & Clinical Cancer Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/bccr.v13i1.8827","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: This study investigated the possible role of Genistein as a combination with Imatinib in controlling leukemia cell line proliferation. Methods: Three cell lines, K562, Kcl22, and CCRF, were cultured and analyzed for MTT, LDH, apoptosis, and cycle cell gene expression in the presence of different dosages of Imatinib and Genistein in combination or separately. Results: Data has shown a decrease in proliferation and an increase in apoptosis activity during combination treatment. LDH assay has shown no additional toxicity due to Genistein consumption in combination therapy. Analysis of the expression of responsible genes for cell cycle demonstrated both G1 (p53, p21 upregulation) and G2 (cdc25c downregulation) inhibitory effect in combination treatment. Conclusion: Altogether, this study suggests thatthe combination treatment of Imatinib and Genistein for leukemia cells resistant to Imatinib can increase treatment efficiency.
染料木素联合伊马替尼对费城阳性白血病细胞增殖抑制作用增强
背景:本研究探讨染料木素联合伊马替尼在控制白血病细胞系增殖中的可能作用。方法:培养K562、Kcl22和CCRF 3株细胞株,分析不同剂量伊马替尼和染料木素联合或单独作用下MTT、LDH、凋亡和周期细胞基因表达的变化。结果:数据显示,在联合治疗期间,细胞增殖减少,细胞凋亡活性增加。LDH测定显示,在联合治疗中,由于染料木素的消耗,没有额外的毒性。对细胞周期相关基因的表达分析显示,联合治疗对G1 (p53、p21上调)和G2 (cdc25c下调)均有抑制作用。结论:综上所述,本研究提示伊马替尼联合染料木素治疗伊马替尼耐药白血病细胞可提高治疗效率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
16
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信